#United States #New York #Securities Fraud #Rosen Law Firm #ADMA Biologics

ADMA Biologics Investors: Take Action Now!

Investors in ADMA Biologics, Inc. who have incurred losses exceeding $100,000 have a crucial opportunity at hand. The Rosen Law Firm, a prominent global firm dedicated to protecting investors' rights, has initiated a class action lawsuit that could lead to significant compensation for affected shareholders. The deadline to step forward as a lead plaintiff is August 10, 2026, and this is an essential chance for those who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026.

Understanding the Legal Context

The securities class action lawsuit stems from allegations that ADMA Biologics engaged in materially misleading business practices that could have affected the investments of countless shareholders. The suit claims that during the stated class period, the company failed to disclose several critical issues, including questionable related party transactions and improper sales tactics, which artificially inflated their revenue appearance. Moreover, the lawsuit alleges that a lack of sufficient internal controls exacerbated the situation, leading investors to suffer significant financial losses when the truth about the company's operations became public knowledge.

What You Should Do Next

If you are an investor who bought ADMA Biologics shares during the class period, now is the time to consider joining this crucial lawsuit. Through a contingency fee arrangement with the Rosen Law Firm, there are no out-of-pocket costs for participating investors. This means you can seek compensation without having to pay upfront legal fees, ensuring that your rights are represented without financial burden.

To participate in the class action, visit the Rosen Law Firm's website for detailed instructions or contact them directly via phone or email. Acting expeditiously is essential, as the October 10 deadline is fast approaching, and you must express your intention to serve as a lead plaintiff if you wish to fulfill this role. If you opt not to take this step, you can still be part of the class, but selecting the right legal representation is crucial.

Why Choose Rosen Law Firm

The Rosen Law Firm is renowned for its expertise in managing high-stakes class action lawsuits and investor protection cases. They stand out due to their impressive track record of successful outcomes, including the largest securities class action settlement against a Chinese company. Their commitment to representing investors globally, along with their experience—ranking among the top firms in the securities class action space—reinforces their ability to navigate these complex legal terrains. The firm’s founding partner has been recognized as a leading figure in the plaintiff’s bar, providing clients with the confidence that their interests will be vigorously defended.

The Importance of Legal Representation

In a scenario where many firms simply act as intermediaries and lack the requisite experience, selecting Rosen Law Firm ensures that you receive expert legal representation. Their attorneys, noted for their accomplishments and recognition in the legal community, are well-versed in the intricacies of securities law and litigation processes.

Conclusion

In summary, the opportunity to join the class action lawsuit against ADMA Biologics is a critical one for investors who believe they have been wronged. With the August 10 deadline approaching rapidly, taking action now could be the difference between receiving the compensation you deserve and missing out entirely. Evaluate your options, reach out to seasoned legal experts, and do not miss this chance to reclaim potential losses.

Contact Rosen Law Firm for More Information

For more details about the case and how to participate, visit Rosen Law Firm's website or call Phillip Kim, Esq. at 866-767-3653. This is a pivotal moment for ADMA Biologics investors — don’t let it pass by without taking the necessary steps toward justice and compensation.